Antisense oligonucleotides for prevention of atherosclerosis and cardiovascular infections

作者: Tomas Kačergius , Dan Ericson

DOI:

关键词:

摘要: The present invention provides isolated antisense oligonucleotides (ASOs) and method for reducing or inhibiting biofilm formation such as in human cardiovascular system on the surfaces contacting with blood and/or serum order to prevent atherosclerosis infections. further compositions biopharmaceutical comprising said ASOs.

参考文章(37)
B. Norrving, P. Puska, S. Mendis, Global atlas on cardiovascular disease prevention and control. Global atlas on cardiovascular disease prevention and control.. ,(2011)
Michael Egholm, Peter Eigil Nielsen, Rolf Hendrik Berg, Ole Buchardt, The use of nucleic acid analogues in diagnostics and analytical procedures ,(1992)
Ole Buchardt, Michael Egholm, Peter E. Nielsen, Rolf H. Berg, Histidine-containing peptide nucleic acids ,(1999)
S Herlitze, J P Ruppersberg, H P Zenner, B Amthor, B Fakler, Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. Journal of Biological Chemistry. ,vol. 269, pp. 16187- 16194 ,(1994) , 10.1016/S0021-9258(17)33991-1
Peter E Nielsen, Pierre Lagriffoul, Ole Di Buchardt, Peptide nucleic acid incorporating a chiral backbone ,(1995)
Antonius Lobberding, Burkhard Mielke, Eckhard Schwenner, Christoph Schwemler, Udo Stropp, Thorsten Potter, Wolfgang Springer, Axel Kretschmer, Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics ,(1994)
Michael Egholm, Peter Eigil Nielsen, Rolf Henrik Berg, Christopher John Stanley, Ole Buchardt, Use of nucleic acid analogues in the inhibition of nucleic acid amplification ,(1993)
Ole Buchardt, Michael Egholm, Peter Eigil Nielsen, Rolf Henrik Berg, Dorte Buchardt executor by, Peptide nucleic acids having enhanced binding affinity and sequence specificity ,(1996)